- mAbxience, a Fresenius Kabi majority-owned group, appoints Jurgen Van Broeck as CEO.
- Broeck brings extensive experience from the pharmaceutical and biosimilar industries.
- The new CEO aims to expand mAbxience’s global footprint and advance its pipeline.
mAbxience, a company in the pharmaceutical industry, has announced the appointment of Jurgen Van Broeck as its new Chief Executive Officer. Broeck, who has been serving as the Global Commercial Director since June 2023, is set to bring his wealth of experience and proven track record to the role.
Before stepping into his new position, Broeck was instrumental in overseeing all commercial, business development, and market access activities at mAbxience. His strategic initiatives have been pivotal in establishing the growth trajectory of the company’s Contract Development and Manufacturing Organisation (CDMO) services.
Under Broeck’s leadership, mAbxience has enhanced its global presence and continued to excel in delivering accessible, high-quality medicines worldwide. His nearly two decades of extensive experience in the healthcare sector, including significant roles at multinational corporations such as Merck and Mundipharma, will undoubtedly be an asset to the company.
In a statement, Broeck expressed his excitement about leading mAbxience in this growth phase. “I am honoured to lead mAbxience as we continue to strive for excellence in everything we do,” said Broeck. “Our mission to provide quality, affordable biological medicines and deliver world-class CDMO services remains at the core of our strategy.”
Overview of outsourcing trends 
